SEC Form 4 · accession 0001178913-26-003473
RedHill Biopharma Ltd. · RDHL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gilead Raday
Officer — Chief Operating Officer
Period of report
Jul 10, 2026
Accepted (ET)
Jul 13, 2026 · 4:03 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001553846
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jul 10, 2026 | S | 14,130,000 | $0.0001 | D | 218,780,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Depositary SharesF3 | — | Jul 10, 2026 | M | 28,150,000 | A | — | — | Ordinary Shares | 28,150,000 | 104,130,000 | D |
Explanation of responses
- F1The reporting person sold 1,413 American Depositary Shares ("ADS") of RedHill Biopharma Inc. (the "Issuer"), each ADS represents 10,000 ordinary shares, par value NIS 0.01 per share, solely to satisfy tax withholding obligations incurred upon the vesting of an aggregate of 4,228 restricted share units granted to him on July 1, 2023, June 24, 2024, March 26, 2025 and January 23, 2026. Such transaction was effected by the trustee appointed in accordance with the regulations set by the Israeli Tax Authority pursuant to a sell to cover policy and does not represent a discretionary trade by the reporting person.
- F2The price reported in Table I Column 4 is $0.6973 per ADS, which would be equivalent to $0.00006973 per ordinary share.
- F3Each ADS is convertible at any time, at the holder's election, for no consideration and has no expiration date.